LLY vs STRO · P/E 39, rev $65.18B vs rev $62.0M
Eli Lilly and Company (LLY) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported LLY revenue for 2025-12-31 was $65.18B. Net income was $20.64B. Revenue was up 44.7% from 2024-12-31 to 2025-12-31. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. STRO currently screens at market cap $470.8M.
Not investment advice. Open the LLY and STRO stock pages for the full models.
Not investment advice.